Page 1

ICONOVO AB Interim report ( Abbreviated version of the original Swedish report ) JANUARY - MARCH 2021 ICONOVO Strategic innovation generates new agreements Key figures in TSEK unless Jan - Mar Jan - Mar Jan - Dec otherwise indicated 2021 2020 2020 Net turnover 2,145 1,932 17,792 Operating profit / loss -7,325 -4,981 -16,717 Cash flow for the period -8,521 -3,732 -27,467 Earnings per share ( SEK ) before full -0.91 -0.55 -2.20 dilution Cash and cash equivalents 53,168 85,424 61,689 Equity 85,651 105,620 92,729 Number of shares at period - end 7,776,000 7,776,000 7,776,000 Number of royalty agreements ** 6 3 5 ** Number of agreements at the end of the period . Significant events 1 January - 31 March • • In January , Iconovo communicated its operational goals for 2021 . • • • In February , Iconovo received its first order for development work for Monash University . This compensation is in addition to the technology access fee previously contracted with the customer . In February , the company announced that the United States Patent and Trademark Office issued an intention to approve ( Notice of Allowance ) a patent for the ICOres inhalation platform . This is the second patent approval for ICOres in the United States . • In February , the first two patent applications for the new ICOpre inhalation platform were submitted . In March , Iconovo signed an agreement with ISR for the development of an inhaled COVID - 19 vaccine . Significant events after the end of the first quarter In April , the company announced that the United States Patent and Trademark Office issued an intention to approve ( Notice of Allowance ) a patent for the ICOone inhalation platform . Iconovo already has approved patents for ICOone in Sweden , Europe ( EPO ) and India .